Skip to main content
    A

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $20.14
    +0.69 (+3.55%)

    Market Cap: $6.77B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +18.04%
    Streak
    7 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.39
    Range$0.34 - $0.41
    7 analysts
    Revenue Consensus
    $856M
    Range$840M - $873M
    6 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.39$0.34 - $0.41--7--
    Sep 26
    Reported Nov 3
    		$0.24$0.23$0.20 - $0.28+4.35%Beat7
    0
    1
    30d
    		+41.2%
    Jun 26
    Reported Jul 30
    		$0.27$0.24$0.20 - $0.26+12.50%Beat5
    2
    1
    30d
    		+8.0%
    Mar 26
    Reported May 7
    		$0.27$0.19$0.18 - $0.21+38.96%Beat5
    1
    0
    30d
    		+28.6%
    Dec 25
    Reported Feb 27
    		$0.21$0.18$0.16 - $0.20+16.67%Beat5
    1
    0
    30d
    		+75.0%
    Sep 25
    Reported Oct 30
    		$0.17$0.14$0.09 - $0.17+21.43%Beat4
    1
    2
    30d
    		+6.3%
    Jun 25
    Reported Aug 5
    		$0.25$0.17$0.16 - $0.20+47.06%Beat4
    1
    0
    30d
    		+56.3%
    Mar 25
    Reported May 2
    		$0.21$0.15$0.13 - $0.16+40.00%Beat3
    0
    1
    30d
    		+50.0%
    Dec 24
    Reported Feb 28
    		$0.12$0.15$0.15 - $0.16-20.00%Miss4
    1
    1
    30d
    		-14.3%
    Sep 24
    Reported Nov 8
    		$0.16$0.14$0.12 - $0.15+14.29%Beat4
    1
    0
    30d
    		-15.8%
    Jun 24
    Reported Aug 9
    		$0.16$0.14$0.12 - $0.17+14.29%Beat4
    1
    0
    30d
    		-15.8%
    Mar 24
    Reported May 3
    		$0.14$0.09$0.08 - $0.11+55.56%Beat5
    No revisions (30d)
    		+16.7%
    Dec 23
    Reported Mar 1
    		$0.14$0.09$0.07 - $0.15+55.56%Beat5
    No revisions (30d)
    		-39.1%

    Key Metrics

    Valuation
    P/E Ratio20.34EV/EBITDA13.30x
    Price/FCF77.35xFCF Yield1.29%
    Profitability
    Profit Margin4.17%Operating Margin16.30%
    ROE70.00%ROIC17.15%
    Financial Health
    Debt/Equity80.86xInterest Coverage13.12x
    Current Ratio2.20xQuick Ratio1.44x
    Trading Statistics
    Beta1.21Avg Volume4.36M
    52-Week High$21.6852-Week Low$11.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$20.66
    SMA 20$20.19
    SMA 50$19.33
    SMA 200$15.91
    EMA 10$20.29
    EMA 20$20.20
    EMA 50$19.50
    EMA 200$16.37

    MACD

    Line: 0.22Signal: 0.37Hist: -0.15

    ADX

    ADX: 20.2+DI: 15.6-DI: 23.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down36.0
    PSAR$21.43

    Bollinger Bands

    Upper Band$21.77
    Lower Band$18.61
    %B Position1563%(Upper)
    Band Width0.48

    RSI (14-Day)

    Neutral
    50.8

    Momentum Oscillators

    Stoch %K32.5
    Stoch %D38.3
    Williams %R-57.8
    ROC (10d)-1.2%
    Momentum-0.24
    CCI (20d)-26.2
    MFI (14d)58.6

    Volatility Measures

    ATR (14d)$0.83(4.1%)
    StdDev (20d)0.79
    Hist Vol35.9%(Moderate)

    Volume Flow

    VWAP$19.96
    OBV88.4M
    AD Line4.8M
    CMF (20d)0.069

    Volume Metrics

    Avg Vol (20d)4.5M
    Vol Ratio0.8x
    VWMA (20d)$20.17

    Pivot Points

    R3$21.25
    R2$20.87
    R1$20.16
    Pivot Point$19.77
    S1$19.06
    S2$18.68
    S3$17.97

    Advanced Oscillators

    TSI9.32
    Ultimate Osc46.9
    KST74.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$796.20M$722.52M$814.32M$784.51M$724.51M$695.42M$730.52M$702.47M$701.78M$659.19M$616.98M$620.04M
    Cost of Revenue$461.69M$402.41M$517.13M$510.54M$438.25M$439.53M$467.64M$432.91M$451.83M$421.13M$427.15M$387.51M
    Gross Profit$334.51M$320.11M$297.19M$273.97M$286.25M$255.89M$262.87M$269.56M$249.95M$238.06M$189.83M$232.53M
    Operating Expenses$204.74M$178.34M$185.16M$203.63M$174.88M$155.54M$187.08M$180.75M$154.48M$248.81M$175.63M$156.88M
    R&D$41.10M$39.92M$36.23M$65.79M$49.98M$41.81M$56.12M$63.06M$37.10M$40.28M$49.91M$41.38M
    SG&A$148.72M$138.86M$146.46M$137.81M$124.27M$118.29M$128.69M$118.69M$116.46M$112.59M$109.00M$113.01M
    Operating Income$129.77M$141.77M$112.03M$70.34M$111.37M$100.35M$75.79M$88.81M$95.47M$-10,746,000$14.19M$75.65M
    Interest Income$-55,043,000$-53,361,000$-56,237,000$-62,814,000$-65,101,000$-56,939,000$-61,662,000$-65,511,000$-65,719,000$-65,703,000$-59,548,000$-50,909,000
    Interest Expense$0$3.51M$56.80M$31.36M$0$0$91.11M$0$75.06M$64.78M$97.65M$52.69M
    Income Before Tax$70.99M$80.18M$55.23M$-5,223,000$51.71M$37.49M$-15,319,000$15.42M$20.41M$-75,522,000$-83,461,000$22.96M
    Income Tax Expense$1.38M$2.18M$5.66M$-23,355,000$16.10M$12.87M$5.42M$3.67M$3.62M$6.16M$9.86M$-2,076,000
    Net Income$69.61M$78.00M$49.57M$18.13M$35.61M$24.62M$-20,742,000$11.76M$16.79M$-81,678,000$-93,344,000$25.03M
    EBITDA$177.90M$184.13M$164.41M$148.06M$183.80M$161.40M$119.29M$147.92M$149.15M$52.51M$78.49M$133.43M
    EBIT$126.03M$137.05M$111.47M$88.96M$116.81M$94.42M$46.34M$80.93M$86.12M$-9,819,000$16.89M$73.87M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AMRX

    News

    Amneal Pharmaceuticals Q3 revenue rises 10% to $863M

    Amneal Pharmaceuticals reported a 10% increase in third-quarter 2026 revenue, reaching $863 million, despite recording a net loss of $22 million. Adjusted earnings per share rose 53% to $0.26...

    grafa.com•11/3/26•Somewhat-Bullish

    Amneal Reports Third Quarter 2026 Financial Results

    Amneal Pharmaceuticals, Inc. announced strong third-quarter 2026 financial results, with net revenue increasing 10% to $863 million and adjusted EBITDA up 30% to $207 million. The company reported a GAAP net loss of $22...

    GlobeNewswire•11/3/26•Somewhat-Bullish

    Parkinson's Disease Therapeutics Market to Reach US$ 12.83 Billion by 2033, Driven by Advances in Neurological Treatments

    The global Parkinson's disease therapeutics market is projected to reach US$12.83 billion by 2033, growing at a CAGR of 8.1% from US$6.40 billion in 2025. This growth is fueled by an aging population...

    openPR.com•10/29/26•Somewhat-Bullish

    Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

    Amarin Corporation reported adjusted earnings of eight cents per ADS for Q3 2026, surpassing the Zacks Consensus Estimate of a loss, despite a 57.9% year-over-year decline. However...

    TradingView•10/29/26•Somewhat-Bullish

    Amneal Pharmaceuticals stock hits a USD 21.46 52-week high

    Amneal Pharmaceuticals (AMRX) reached a 52-week high of USD 21.46 on October 27, 2026, driven by strong Q2 revenue of USD 796.20 million and adjusted EPS of USD 0.30...

    ad-hoc-news.de•10/27/26•Bullish

    AMRX Valuation and Fair Value

    P/E
    20.3x
    Forward P/E
    17.3x
    EV/EBITDA
    13.3x
    P/FCF
    77.4x
    PEG
    1.9x
    P/B
    194.7x
    See GNG's fair value

    AMRX Profitability: Margins, ROIC and FCF

    Gross margin
    39.3%
    Operating margin
    16.3%
    Net margin
    4.2%
    ROIC
    17.1%
    ROE
    70.0%
    FCF margin
    2.7%
    FCF yield
    1.3%

    AMRX Competitors

    CompanyTicker
    Merus BVMRUS
    Ionis Pharmaceuticals IncIONS
    Kiniksa Pharmaceuticals LtdKNSA
    Lantheus Holdings IncLNTH
    Axsome Therapeutics IncAXSM
    Teleflex IncorporatedTFX
    Praxis Precision Medicines IncPRAX
    Oruka Therapeutics, Inc.ORKA

    Sector: Healthcare

    AMRX Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    3
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    AMRX Bull Case vs Bear Case

    Bull case

    • AMRX earns a 17.1% return on invested capital.
    • AMRX beat EPS estimates in 87.5% of its last 8 reported quarters.
    • AMRX grew quarterly revenue 10.0% year over year.

    Bear case

    • AMRX has a debt-to-equity ratio of 80.9x.

    AMRX Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    20.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.39

    AMRX Earnings Date

    AMRX reports Feb 25, 2027, before the open. The date is estimated.

    AMRX Earnings Call

    The latest AMRX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    AMRX ETF Holders

    GNG tracks 13 ETFs that hold AMRX. The largest weights:

    1. State Street SPDR S&P Pharmaceuticals ETF (XPH), 2.46% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.24% of the fund
    3. iShares Core S&P Small-Cap ETF (IJR), 0.23% of the fund
    4. Vanguard Morningstar Small-Cap Value ETF (VBR), 0.08% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.06% of the fund
    Open the ETF Stock Exposure tool for AMRX

    See insider activity

    Frequently Asked Questions About AMRX

    When does AMRX report earnings?

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is expected to report earnings on Feb 25, 2027.

    Does AMRX pay dividends?

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) does not currently pay a regular dividend.

    What is AMRX's P/E ratio?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has a price-to-earnings (P/E) ratio of 20.34.

    What is AMRX's market cap?

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a market capitalization of $6.77B with a current stock price of $20.14.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In